• On 24 March 2026, Medtronic announced a distribution agreement with Merit Medical Systems to offer ViaVerte, an FDA-cleared, minimally invasive basivertebral nerve ablation system for chronic vertebrogenic lower back pain, extending an existing supply relationship between the two companies.
• This agreement gives Merit access to Medtronic’s broad pain management distribution network, potentially increasing physician adoption of ViaVerte and reinforcing Merit's position in outpatient spine interventions.
• Next, we’ll assess how this expanded Medtronic partnership around ViaVerte may influence Merit Medical Systems’ longer-term investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical Systems, you need to believe in its ability to grow through minimally invasive therapies, disciplined acquisitions, and improved profitability, while managing reimbursement and cost pressures. The ViaVerte distribution deal with Medtronic strengthens Merit’s presence in outpatient spine and pain interventions, but does not change that the most immediate catalyst remains securing timely, clean reimbursement for WRAPSODY CIE, and the biggest near term risk is that reimbursement or broader pricing pressures slow the payoff from its premium product portfolio.

The recent US commercial release of the Resilience Through the Scope Esophageal Stent is particularly relevant alongside ViaVerte, because together they highlight Merit’s push deeper into higher value interventional niches within endoscopy and pain. If these launches translate into sustained procedure adoption through partners and existing channels, they could help offset tariffs, China volume based purchasing pressure, and elevated operating expenses if those headwinds continue.

However, investors should also be aware that if reimbursement for WRAPSODY CIE remains delayed or constrained, then ...

Merit Medical Systems' narrative projects $1.8 billion revenue and $197.2 million earnings by 2028. This requires 7.0% yearly revenue growth and about a $78 million earnings increase from $119.1 million today.

Uncover how Merit Medical Systems' forecasts yield a $103.55 fair value, a 51% upside to its current price.

Exploring Other Perspectives

Two members of the Simply Wall St Community currently place Merit’s fair value between US$82.11 and US$103.55, underlining how much opinions can differ. You should weigh those views against the dependence on securing and maintaining premium reimbursement for products like WRAPSODY CIE, which could influence how effectively Merit converts its innovation pipeline into earnings over time.

Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth as much as 51% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merit Medical Systems research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.

No Opportunity In Merit Medical Systems?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.